P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA
Amira Marouf,N. Molinari,David Sibon,A. Cottereau,Salim Kanoun,C. Antoine,Pierre-Edouard Debureaux,Doriane Cavalieri,Luc-Matthieu Fornecker,Rene-Olivier Casasnovas,Charles Herbaux,Sandy Amorim,Cédric Rossi,Didier Bouscary,Pauline Brice,Hervé Ghesquières,Jerome Tamburini,Bénédicte Deau +17 more
TL;DR: In this article , BV maintenance was associated with better survival outcome in patients with relapsed/refractory Hodgkin lymphoma (R/R HL) compared to intensive tandem auto/auto or auto/allo transplant strategies.
Journal ArticleDOI
Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment
Sandy Amorim,Isabelle Fleury,Nicolas Mounier,Stephanie Harel,Pauline Brice,Catherine Thieblemont +5 more
TL;DR: A retrospective analysis evaluating the efficacy of mesna/ifosfamide, mitoxantrone, and etoposide with or without rituximab in relapsed/ refractory diffuse large B-cell lymphoma patients failing second-line treatment with R-DHAX in a single French center.
Journal ArticleDOI
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
P. L. Zinzani,Armando Santoro,Giuseppe Gritti,Pauline Brice,Paul M. Barr,John Kuruvilla,David Cunningham,Justin Kline,Nathalie A. Johnson,Neha Mehta-Shah,Julie Lisano,Rachael Wen,Alev Akyol,Alison J. Moskowitz +13 more
TL;DR: In this article , Nivolumab and brentuximab vedotin (BV) showed promising early efficacy in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) in the phase I/II open-label, multicenter CheckMate 436 study; they report safety and efficacy findings from the 3-year follow-up.
Journal ArticleDOI
P1351: characterizing allogeneic stem cell transplantation safety in patients with hematologic malignancies after pembrolizumab therapy
John Kuruvilla,P. Armand,Alex F. Herrera,Vincent Ribrag,Pauline Brice,Catherine Thieblemont,Bastian von Tresckow,E Kim,Patricia Marinello,Samhita Chakraborty,Richard Orlowski,Pier Luigi Zinzani +11 more
TL;DR: Data is presented from an analysis from 4 KEYNOTE phase 1-3 studies to describe predetermined complications in patients who received allo-SCT following pembrolizumab therapy to estimate cumulative incidence of post–allo-S CT transplant-related mortality (TRM) estimated with relapse as a competing risk.
Practical Events in the Management of a Collodion Baby
Pauline Laly,Saskia Ingen-Housz-Oro,Marie Beylot-Barry,L. Verneuil,Henri Adamski,Pauline Brice,Martine Bagot +6 more
TL;DR: The rapidity of the response supports the role of vinblastine instead of spontaneous regression in these patients with multifocal lesions and a long-term history of refractory C-ALCL, and its place as second-line treatment could be considered with failure of methotrexate and perhaps as first- line treatment in the case of contraindication to metotrexate.